跳轉至內容
Merck
  • High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.

High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.

Annals of surgical oncology (2017-09-22)
Pinjie Bao, Takehiko Yokobori, Bolag Altan, Misaki Iijima, Youko Azuma, Ryoichi Onozato, Toshiki Yajima, Akira Watanabe, Akira Mogi, Kimihiro Shimizu, Toshiteru Nagashima, Yoichi Ohtaki, Kai Obayashi, Seshiru Nakazawa, Tuya Bai, Reika Kawabata-Iwakawa, Takayuki Asao, Kyoichi Kaira, Masahiko Nishiyama, Hiroyuki Kuwano
摘要

Known as a microtubule-destabilizing protein, STMN1 (gene symbol: STMN1) regulates the dynamics of microtubules, cell cycle progress, and chemo-resistance against taxane agents. It is highly expressed in various human cancers and involved in cancer progression as well as poor prognosis. Expression of STMN1 was examined by immunohistochemistry using FFPE tissue sections from 186 patients with lung squamous cell carcinoma (LSCC). Analysis of STMN1 suppression was performed for STMN1 small interfering RNA (siRNA)-transfected LSCC cell lines to determine the change in proliferation, invasive and apoptosis abilities, and paclitaxel sensitivity. The cytoplasmic STMN1 expression in LSCC was higher than in normal tissues. The high expression was significantly associated with vascular invasion (P = 0.0477) and poor prognosis. In addition, the proliferating and invasive abilities were decreased, and the apoptosis ability and paclitaxel sensitivity were increased in STMN1-suppressed LSCC cells compared with control cells. The results suggest that STMN1 is a prognostic factor that also is associated with caner progression and chemo-resistance. Therefore, STMN1 could be a predictor for poor prognosis and a potential therapeutic target in LSCC.